Fox Chase Cancer Center

Site:	Fox Chase Cancer Center			Go to their website
Address:	333 Cottman Ave
City:	Philadelphia
State:	PA
Zip:	19111
Country:	USA

37 trials at this site

Phase	Trial [desc]	Trial Status	Site Status	Drug	NCT#
1	(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors	Active, not recruiting	Closed	BLU-285	NCT02508532
2	Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors	Completed	Closed	Linsitinib (OSI-906)	NCT01560260
3	Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor	Terminated	Closed	Imatinib + Bevacizumab	NCT00324987
2	Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST) (Novartis CSTI571BUS282)	Completed	Closed	Imatinib	NCT00867113
2	Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors	Completed	Closed	Imatinib + RAD001	NCT01275222
3	Efficacy and Safety of AMN107 Compared With Current Treatment Options in Patients With GIST Who Have Failed Both Imatinib and Sunitinib (ENEST)	Completed	Closed	Nilotinib	NCT00471328
3	Efficacy and Safety of AMN107 Compared With Current Treatment Options in Patients With GIST Who Have Failed Both Imatinib and Sunitinib - Extension	Completed	Closed	Nilotinib	NCT00488150
2	A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST	Completed	Closed	Imatinib + AT13387	NCT01294202
1/2	A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)	Active, not recruiting	Closed	THE-630	NCT05160168
2	A Study of the Efficacy and Safety of Imatinib Mesylate in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing c-Kit Gene (Extension of US Phase II study, B2222)	Completed	Closed	Imatinib	NCT00237185
1/2	A Study of DCC-3116 in Combination with Anticancer Therapies in Participants with Advanced Malignancies	Recruiting	Active	DCC-3116 + Ripretinib	NCT05957367
3	A Study of DCC-2618 vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib (intrigue)	Active, not recruiting	Active	QINLOCK Ripretinib DCC-2618 SUTENT Sunitinib	NCT03673501
2	A Study Evaluating STA-9090 in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST)	Completed	Closed	STA-9090	NCT01039519
1	A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies	Active, not recruiting	Closed	QINLOCK Ripretinib DCC-2618	NCT02571036
1	A Pilot Study of CS-1008, A Humanized Monoclonal Antibody Targeting Death Receptor 5, Alone or In Combination with Imatinib Mesylate or Sunitinib Malate In Subjects with Advanced Gastrointestinal Stromal Tumors	Withdrawn	Closed	CS-1008 and Imatinib or Sunitinib
2	A Phase 2 Trial of Ponatinib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor	Completed	Closed	Ponatinib (Iclusig)	NCT01874665
1	A First-in-human (FIH) Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) [Study ID: StrateGIST1]	Recruiting	Active	IDRX-42	NCT05489237